182 related articles for article (PubMed ID: 35871104)
1. Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review.
McCullagh J; Cardigan R; Brunskill SJ; Bullock T; Doree C; Estcourt L; Huish S; Sandercock J; Green L
Blood Rev; 2022 Nov; 56():100989. PubMed ID: 35871104
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ABO antibody titration, IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion.
Bastos EP; Castilho L; Bub CB; Kutner JM
Transfus Med; 2020 Aug; 30(4):317-323. PubMed ID: 32484285
[TBL] [Abstract][Full Text] [Related]
3. Severe acute haemolytic transfusion reaction secondary to a plasma incompatible group B platelet transfusion.
Bienz M; Gupta A; Goldstein J; Kennedy J; Lin Y
Transfus Med; 2023 Apr; 33(2):188-193. PubMed ID: 36380475
[TBL] [Abstract][Full Text] [Related]
4. Delayed intravascular haemolysis following multiple asymptomatic ABO-incompatible red blood cell transfusions in a patient with hepatic failure.
Tormey CA; Stack G
Vox Sang; 2008 Oct; 95(3):232-5. PubMed ID: 19121188
[TBL] [Abstract][Full Text] [Related]
5. Complement activating ABO anti-A IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible transfusions.
Pandey P; Anani WQ; Pugh T; Gottschall JL; Denomme GA
J Transl Med; 2020 May; 18(1):216. PubMed ID: 32466782
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets.
Mair B; Benson K
Transfusion; 1998 Jan; 38(1):51-5. PubMed ID: 9482394
[TBL] [Abstract][Full Text] [Related]
7. ABO-incompatible platelets are associated with increased transfusion reaction rates.
Malvik N; Leon J; Schlueter AJ; Wu C; Knudson CM
Transfusion; 2020 Feb; 60(2):285-293. PubMed ID: 31912889
[TBL] [Abstract][Full Text] [Related]
8. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories.
Fung MK; Downes KA; Shulman IA
Arch Pathol Lab Med; 2007 Jun; 131(6):909-16. PubMed ID: 17550318
[TBL] [Abstract][Full Text] [Related]
9. Hemolysis following platelet transfusions from ABO-incompatible donors.
Pierce RN; Reich LM; Mayer K
Transfusion; 1985; 25(1):60-2. PubMed ID: 2578692
[TBL] [Abstract][Full Text] [Related]
10. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.
Tomac G; Bojanić I; Mazić S; Vidović I; Raos M; Ćepulić BG; Seiwerth RS; Kelečić J; Labar B
Blood Transfus; 2018 Jul; 16(4):397-404. PubMed ID: 28488966
[TBL] [Abstract][Full Text] [Related]
11. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.
Berséus O; Boman K; Nessen SC; Westerberg LA
Transfusion; 2013 Jan; 53 Suppl 1():114S-123S. PubMed ID: 23301963
[TBL] [Abstract][Full Text] [Related]
12. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
Josephson CD; Castillejo MI; Grima K; Hillyer CD
Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
[TBL] [Abstract][Full Text] [Related]
13. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions.
Karafin MS; Blagg L; Tobian AA; King KE; Ness PM; Savage WJ
Transfusion; 2012 Oct; 52(10):2087-93. PubMed ID: 22339320
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of ABO Antibodies in Group O Malaysian Blood Donors.
Saidin NIS; Noor NHM; Yusoff SM; Sauli MS
Malays J Med Sci; 2023 Aug; 30(4):61-70. PubMed ID: 37655148
[TBL] [Abstract][Full Text] [Related]
15. Repeat ABO-incompatible platelet transfusions leading to haemolytic transfusion reaction.
Sadani DT; Urbaniak SJ; Bruce M; Tighe JE
Transfus Med; 2006 Oct; 16(5):375-9. PubMed ID: 16999762
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of A plasma for incompatible patients.
Olsen G; Passwater M; Huggins M; Mukhtar F; Pelletier P
Transfusion; 2021 Feb; 61(2):375-378. PubMed ID: 33219552
[TBL] [Abstract][Full Text] [Related]
17. ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.
Chen Y; Wan X; Cao Y; Wang H; Han D; Zhang Y; Yao W; Song K; Fan Q; Zhu X; Sun Z; Liu H
Blood Transfus; 2022 Mar; 20(2):156-167. PubMed ID: 34369864
[TBL] [Abstract][Full Text] [Related]
18. Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy.
Pagano MB; Katchatag BL; Khoobyari S; Van Gerwen M; Sen N; Rebecca Haley N; Gernsheimer TB; Hess JR; Metcalf RA
Transfusion; 2019 Apr; 59(4):1246-1251. PubMed ID: 30592057
[TBL] [Abstract][Full Text] [Related]
19. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
Maciej Zaucha J; Mielcarek M; Takatu A; Little MT; Gooley T; Baker J; Maloney DG; Sandmaier BM; Maris M; Chauncey T; Storb R; Torok-Storb B
Br J Haematol; 2002 Dec; 119(3):740-50. PubMed ID: 12437653
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of ABO-incompatible transfusion].
Fujii Y
Masui; 2011 Jan; 60(1):47-54. PubMed ID: 21348250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
